

Unraveling the Molecular Mechanisms of Neurodegenerative Diseases: A Biomedical Review

Leonn Srinagesh*

Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, USA

Abstract

Biomedical science encompasses a diverse array of disciplines aimed at understanding human health and disease at the molecular, cellular, and organismal levels. This comprehensive review explores the significant contributions of biomedical science to medical research and healthcare. The article delves into key areas such as genetics, molecular biology, immunology, and pharmacology, highlighting breakthroughs that have revolutionized the diagnosis, treatment, and prevention of diseases. Furthermore, it discusses the promising prospects of biomedical engineering and precision medicine in improving patient outcomes and public health. By shedding light on the intricacies of biomedical science, this review underscores its indispensable role in advancing our understanding of human biology and its potential to transform the future of healthcare.

Keywords: Biomedical science • Immunology • Precision medicine

Introduction

Nanomedicine is a cutting-edge interdisciplinary field that harnesses the unique properties of nanomaterials to revolutionize healthcare. By manipulating materials at the nanoscale level, nanomedicine offers innovative solutions for diagnosing, treating, and preventing various diseases. Nanoparticles, nanoscale drug delivery systems, and nanosensors are just a few examples of the transformative applications of nanotechnology in medicine. This article explores the exciting potential of nanomedicine and its role in addressing health challenges and improving patient outcomes. Neurodegenerative diseases are a group of debilitating disorders characterized by the progressive degeneration of nerve cells (neurons) in the central nervous system. These diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS), result in a gradual decline in cognitive, motor, and sensory functions. Despite extensive research, the precise molecular mechanisms underlying these diseases remain complex and multifaceted. This article delves into the current understanding of the molecular mechanisms involved in neurodegenerative diseases from a biomedical perspective [1].

Literature Review

Biotechnology has revolutionized drug discovery by enabling the identification and characterization of therapeutic targets with unprecedented precision. Tools like high-throughput screening and computational biology have accelerated the process of identifying potential drug candidates, thereby expediting the early stages of drug development. Recombinant DNA technology lies at the core of biotechnology-driven drug development. The ability to clone, modify, and express genes in heterologous systems has led to the production of therapeutic proteins and peptides, including insulin, growth factors, and monoclonal antibodies. These biopharmaceuticals have become cornerstones of modern medicine, offering targeted therapies with reduced side effects. Monoclonal antibodies have emerged as a powerful class of therapeutics, capable of targeting specific antigens

and modulating the immune response. Biotechnology-driven advancements in immuno-oncology have revolutionized cancer treatment, providing new avenues for immunotherapies and personalized medicine approaches [2,3].

Discussion

Gene therapy represents a ground breaking area in drug development, with the potential to cure genetic diseases by introducing functional genes or modifying existing ones. The advent of genome editing technologies, such as CRISPR/Cas9, has further expanded the possibilities of precise gene manipulation, offering potential cures for a wide range of inherited disorders. Despite the remarkable progress, biotechnology-driven drug development faces challenges related to regulatory approvals, manufacturing complexities, and high costs [4]. The intricate nature of biopharmaceuticals necessitates stringent quality control and safety assessments, which pose unique challenges compared to traditional small-molecule drugs. The future of drug development lies in harnessing the full potential of biotechnology, further exploring multi-omics approaches, and integrating AI-driven technologies to accelerate drug discovery and development. Biotechnology-driven drug therapies hold immense promise for addressing unmet medical needs, delivering precise treatments, and transforming the landscape of healthcare. In response to injury and protein aggregates, the brain's immune cells, including microglia and astrocytes, become activated, leading to a state of chronic neuroinflammation. While inflammation is a protective mechanism, sustained activation of immune cells can release pro-inflammatory cytokines and reactive molecules that contribute to neuronal damage. Neurons are particularly susceptible to oxidative stress due to their high metabolic activity and limited regenerative capacity. Oxidative stress occurs when the balance between Reactive Oxygen Species (ROS) and antioxidant defenses is disrupted. The accumulation of ROS damages cellular components, including lipids, proteins, and DNA. This oxidative damage contributes to neuroinflammation and neuronal death observed in neurodegenerative diseases [5,6].

Conclusion

Biotechnology has ushered in a new era of drug development, seamlessly integrating science and technology to redefine medicine's frontiers. From biopharmaceuticals and gene therapies to personalized medicine approaches, biotechnology-driven drug development continues to forge ahead, shaping the future of healthcare. As we embrace the transformative power of biotechnology, we move closer to a new era of medicine, where targeted, precise, and patient-centric therapies offer hope and healing to patients worldwide. In conclusion, neurodegenerative diseases are complex and multifaceted disorders that arise from the interplay of various molecular mechanisms. Protein misfolding, oxidative stress, mitochondrial dysfunction, neuroinflammation, excitotoxicity,

*Address for Correspondence: Leonn Srinagesh, Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, USA, E-mail: leonnsrinagesh23@gmail.com

Copyright: © 2023 Srinagesh L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 27 March, 2023, Manuscript No. jpbs-23-109772; **Editor Assigned:** 29 March, 2023, PreQC No. P-109772; **Reviewed:** 13 April, 2023, QC No. Q-109772; **Revised:** 18 April, 2023, Manuscript No. R-109772; **Published:** 25 April, 2023, DOI: 10.37421/2155-9538.2023.13.345

genetic factors, impaired autophagy, epigenetic modifications, and blood-brain barrier dysfunction collectively contribute to the progression of these diseases. A comprehensive understanding of these molecular mechanisms is crucial for developing effective therapeutic strategies aimed at slowing down or halting the progression of neurodegenerative diseases and improving the quality of life for affected individuals.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Batool, Shadab, Hussain Raza, Jawwad Zaidi and Saba Riaz, et al. "Synapse formation: From cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders." *J Neurophysiol* (2019).
2. S Stem, Maxwell and Thomas W Gardner. "Neurodegeneration in the pathogenesis of diabetic retinopathy: Molecular mechanisms and therapeutic implications." *Curr Med Chem* 20 (2013): 3241-3250.
3. Wu, Shi-Bei and Yau-Huei Wei. "AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: Implication of the cell survival in mitochondrial diseases." *Biochim Biophys Acta Mol Basis D* 1822 (2012): 233-247.
4. Myszczyńska, Monika A., Poojitha N. Ojames, Alix MB Lacoste and Daniel Neil, et al. "Applications of machine learning to diagnosis and treatment of neurodegenerative diseases." *Nat Rev Neurol* 16 (2020): 440-456.
5. Babić Leko, Mirjana, Vera Župunski, Jason Kirincich and Dinko Smilović, et al. "Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion." *Behav Neurol* 2019 (2019).
6. Hannan, Md Abdul, Raju Dash, Abdullah Al Mamun Sohag and Il Soo Moon. "Deciphering molecular mechanism of the neuropharmacological action of fucosterol through integrated system pharmacology and *in silico* analysis." *Mar Drugs* 17 (2019).

How to cite this article: Srinagesh, Leonn. "Unraveling the Molecular Mechanisms of Neurodegenerative Diseases: A Biomedical Review." *J Bioengineer & Biomedical Sci* 13 (2023): 345.